To include your compound in the COVID-19 Resource Center, submit it here.

Subcutaneous RoActemra tocilizumab regulatory update

Roche said the European Commission approved a subcutaneous formulation of RoActemra tocilizumab to treat patients with severe, active and progressive rheumatoid

Read the full 210 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE